To explore the application of HiR (Zebtorizumab, Lenalidomide) + X (targeted drug) guided by NGS molecular typing, the aim is to assess the therapeutic efficacy and safety in newly diagnosed unfit or frail elderly patients with DLBCL aged ≥70 years, and to investigate the genetic subtypes that may benefit from HiR-X.
Age ≥ 70 years;
ECOG score 0-3;
Rated as "unfit" or "frail" on the simplified geriatric assessment (sGA);
Histologically confirmed CD20-positive diffuse large B-cell lymphoma [diagnostic criteria according to WHO 2016], excluding transformed type 2 DLBCL;
Patients with central nervous system involvement at the onset of the disease;
Known human immunodeficiency virus (HIV) infection;
Pregnant or lactating women;
Other tumors requiring treatment;